Research and Technology Management
|
|
- Barnaby King
- 6 years ago
- Views:
Transcription
1 Grants & Contracts Awards Processed by Grants & Contracts Join us as we congratulate the investigators listed below who have recently received a new or competitive renewal award (Based on information available in Grants Central as of 3/1/13): *Total award amount reflects Direct Costs only for the duration of the project February 2013 Principal Investigator: Jacqueline F. Bromberg, MD, PhD Department/Program: Medicine/Breast Cancer Project Title: Characterization and Functional Analysis of Breast Cancer-Derived Exosomes in Malignant Progression Total Award* Amount: $96,080 Award Date: 02/08/13 Project Duration: 5 Years Awarding Agency: Weill Medical College of Cornell University/National Institutes of Health Principal Investigator: Ross Levine, MD Department/Program: Medicine/Human Oncology & Pathogenesis Program (HOPP) Project Title: Role of TET2 Mutations in Malignant Transformation and Acute Myeloid Leukemia Total Award* Amount: $2,375,521 Award Date: 02/07/13 Project Duration: 5 Years Awarding Agency: National Cancer Institute Principal Investigator: Ana Ortega Molina, PhD Department/Program: Cancer Biology & Genetics Project Title: Epigenetics of Lymphoid Malignancies Total Award* Amount: $157,143 Award Date: 02/01/13 Awarding Agency: Leukemia and Lymphoma Society Principal Investigator: Chris Sander, PhD Department/Program: Epidemiology & Biostatistics/Biostatistics/Computational Biology Project Title: TARGET Analysis Portal Proposal Total Award* Amount: $186,502 Award Date: 02/01/13 Awarding Agency: SAIC-Frederick/National Cancer Institute 1 Memorial Sloan-Kettering Cancer Center
2 Principal Investigator: Lorenz Studer, MD Department/Program: Neurosurgery/Departmental/Developmental Biology Project Title: Oculomotor Resistance in ALS Total Award* Amount: $94,300 Award Date: 02/20/13 Awarding Agency: Project A.L.S. Principal Investigator: Larissa K.F. Temple, MD, FACS, FRCS(C) Department/Program: Surgery/Colorectal Project Title: Randomized Early Intervention Study to Improve Bowel Function in SPS Patients Total Award* Amount: $49,376 Award Date: 02/13/13 Awarding Agency: American Society of Colon and Rectal Surgeons Principal Investigator: Talia Zaider PhD Department/Program: Psychiatry Project Title: Theraputic Pathways to Improving End of Life Outcomes Among Families in Palliative Care Total Award* Amount: $24,250 Award Date: 02/11/13 Project Duration: 4 Years Awarding Agency: National Cancer Institute INTERNAL COMPETITION Principal Investigator: John Chodera, PhD Department/Program: Computational Biology Award Date: 02/01/13 January 2013 Principal Investigator: Cameron Brennan, MD Department/Program: Neurosurgery Project Title: Elucidating Mechanisms of Histone H3.3 Mutants-Mediated Oncogenesis in Pediatric Brain Cancers Total Award* Amount: $70,000 2 Memorial Sloan-Kettering Cancer Center
3 Principal Investigator: Yu Chen, MD Department/Program: Human Oncology & Pathogenesis Program (HOPP) Project Title: Elucidating Mechanisms of Histone H3.3 Mutants-Mediated Oncogenesis in Pediatric Brain Cancers Total Award* Amount: $208,000 Principal Investigator: Ping Chi, MD Department/Program: Medicine Project Title: Elucidating Mechanisms of Histone H3.3 Mutants-Mediated Oncogenesis in Pediatric Brain Cancers Total Award* Amount: $70,000 Award Date: 01/14/13 Principal Investigator: Jarrod Dudakov, PhD Department/Program: Immunology Project Title: Role of Interleukin-22 (IL-22) in Thymic Function Total Award* Amount: $100,000 Award Date: 01/25/13 Awarding Agency: American Society of Hematology Principal Investigator: Ira J. Dunkel, MD Department/Program: Pediatrics Project Title: Children's Oncology Group: Per Case Reimbursement from NIH COG Chair Grant Total Award* Amount: $12,500 Awarding Agency: Children's Hospital of Philadelphia/National Cancer Institute Principal Investigator: Emily Foley, PhD Department/Program: Cell Biology 3 Memorial Sloan-Kettering Cancer Center
4 Principal Investigator: Alan M. Hanash, MD, PhD Department/Program: Medicine Project Title: IL-22, Innate Lymphoid Cells, and the Protection of Epithelial Tissues from GVHD Total Award* Amount: $150,000 Award Date: 01/25/13 Awarding Agency: American Society of Hematology Principal Investigator: Daniel Heller, PhD Department/Program: Molecular Pharmacology & Chemistry Principal Investigator: Ross Levine, MD Department/Program: Medicine/Human Oncology & Pathogenesis Program (HOPP) Project Title: Discovery of AID-dependent Epigenetic Mechanisms in Hematological Malignancies Total Award* Amount: $166,666 Principal Investigator: Ross Levine, MD Department/Program: Medicine/Human Oncology & Pathogenesis Program (HOPP) Project Title: Therapeutic Targeting of IDH1 and IDH2 Mutations in Acute Myeloid Leukemia (AML) and Chondrosarcoma Total Award* Amount: $249,778 Principal Investigator: Wendy G. Lichtenthal, PhD Department/Program: Psychiatry & Behavioral Sciences Project Title: Survivorship Project: ACS and MSKCC Collaboration to Adapt and Refine Meaning-Centered Group Psychotherapy for Breast Cancer Survivors Through Focus Groups and Intervention Evaluations Total Award* Amount: $384,424 Award Date: 01/23/13 Awarding Agency: American Cancer Society 4 Memorial Sloan-Kettering Cancer Center
5 Principal Investigator: Brian P. Marr, MD Department/Program: Surgery/Ophthalmic Oncology Project Title: Development of sd-rxrnas as Therapy for Retinoblastoma and Other Malignancies Total Award* Amount: $13,059 Award Date: 01/30/13 Awarding Agency: RXi Pharmaceuticals/ National Cancer Institute Principal Investigator: Joseph R. Osborne, MD, PhD Department/Program: Radiology/Molecular Imaging and Therapy Project Title: Immuno-PET With Anti-PSMA 89Zr-J591 mab For Molecular Imaging of Prostate Cancer Total Award* Amount: $108,750 Award Date: 01/28/13 Project Duration: 7 Months Awarding Agency: National Cancer Institute Principal Investigator: Cindy Puente, MA Department/Program: Cell Biology Project Title: Sensing and Relaying Autophagic Signaling by Ulk Kinase Complex Total Award* Amount: $126,696 Award Date: 01/25/13 Awarding Agency: National Institute of General Medical Sciences Principal Investigator: Raajit K. Rampal, MD, PhD Department/Program: Human Oncology & Pathogenesis Program (HOPP) Project Title: The Role of WT1 in Epigenetic Alterations in Acute Myeloid Leukemia Total Award* Amount: $100,000 Award Date: 01/17/13 Awarding Agency: American Society of Hematology Principal Investigator: Gary Schwartz, MD Department/Program: Medicine/Melanoma and Sarcoma Project Title: Therapeutic Targeting of IDH1 and IDH2 Mutations in Acute Myeloid Leukemia (AML) and Chondrosarcoma Total Award* Amount: $249,778 Principal Investigator: Martin S. Tallman, MD Department/Program: Medicine/Leukemia 5 Memorial Sloan-Kettering Cancer Center
6 Project Title: ECOG and ACRIN Consolidation Total Award* Amount: $13,430 Award Date: 01/09/13 Awarding Agency: Eastern Cooperative Oncology Group/National Cancer Institute Principal Investigator: Richard White, MD, PhD Department/Program: Cancer Biology & Genetics INTERNAL COMPETITION Principal Investigator: Samuel Danishefsky, PhD Department/Program: Molecular Pharmacology & Chemistry Project Title: Testing the Immunogenicity of a New Unimolecular Vaccine Total Award* Amount: $50,000 Award Date: 01/23/13 Awarding Agency: Experimental Therapeutics Center 6 Memorial Sloan-Kettering Cancer Center
New drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationResearch and Technology Management
Office of Technology Development - Sponsored Research Agreements Join us as we congratulate the Principal Investigators of new industry sponsored research agreements listed below: January 2012 Principal
More informationChanging AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight
Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight Co-Moderators: Rick Winneker, PhD, Senior Vice President, Research, Leukemia & Lymphoma Society Mike
More informationPRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationFACULTY MEMBERSHIP APPLICATION Tulane Cancer Center
FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,
More informationNCCN National Comprehensive Cancer Network Directory Information
Please provide the information requested below. The information contained herein is for NCCN purposes only and will not be published without your express written consent below. Name: Last First Middle
More information*Total award amount reflects Direct Costs only for the duration of the project
Grants & Contracts Awards Join us as we congratulate the investigators listed below who have recently received a new or competitive renewal award: *Total award amount reflects Direct Costs only for the
More informationPERSONALIZED PSYCHO-ONCOLOGY
Memorial Sloan Kettering Cancer Center is pleased to present: PERSONALIZED PSYCHO-ONCOLOGY A CASE-BASED APPROACH Saturday, October 12, 2019 Rockefeller Research Laboratories 430 East 67th Street New York,
More informationCONTRACTING ORGANIZATION: Memorial Sloan-Kettering Cancer Center New York, NY 10065
Award Number: W81XWH-10-1-0699 TITLE: Randomized Phase II Trial of Adjuvant WT-1 Analog Peptide Vaccine in Patients with Malignant Pleural Mesothelioma after Completion of Multimodality Therapy PRINCIPAL
More informationEnasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia
Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM
More informationFacts On Leukemia By American Cancer Society
Facts On Leukemia By American Cancer Society If you are searching for a book Facts on Leukemia by American Cancer Society in pdf format, then you've come to the loyal site. We presented the complete edition
More informationA Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL
A service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: CABL001X2101 Previous Study Return to List
More informationGenetic analysis and preclinical modeling of leukemic transformation of myeloproliferative neoplasms: Implications for therapeutic strategies
Genetic analysis and preclinical modeling of leukemic transformation of myeloproliferative neoplasms: Implications for therapeutic strategies Raajit Rampal, MD, PhD Assistant Attending Physician Leukemia
More informationGenetics of MPNs insights from genomic and functional studies
Genetics of MPNs insights from genomic and functional studies January 10, 2012 Ross L. Levine, M.D. Human Oncology and Pathogenesis Program Leukemia Service, Department of Medicine Memorial Sloan Kettering
More informationThe 2015 donations will be transformative:
2015 Impact Funding Allocations Cycle for Survival is determined to beat rare cancers by powering groundbreaking research. Participants and donors fight so all patients have the treatment options they
More informationPhase 2b trial met key clinical objectives and is being discontinued early by the sponsor
NEWS RELEASE SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax (nelipepimut-s) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients 6/1/2018 Phase 2b trial met key
More informationGrants & Contracts Awards
Grants & Contracts Awards Processed by Grants & Contracts Join us as we congratulate the investigators listed below who have recently received a new or competitive renewal award: *Total award amount reflects
More informationENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY
ENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir
More informationASCO 2018 Summary of Presentation. May 16, 2018
ASCO 2018 Summary of May 16, 2018 ASCO: Accepted s Oral presentations DS-8201 Pexidartinib Poster discussions U3-1402 Quizartinib DS-3032 Poster presentations Trial-in-Progress DS-8201 U3-1402 DS-1062
More informationONCOLOGY MEDICAL HOME ACCREDITATION
2015 Community Oncology Alliance 1 ONCOLOGY MEDICAL HOME ACCREDITATION Panel Moderator: Bo Gamble Director of Strategic Practice Initiatives, Community Oncology Alliance 1 ONCOLOGY MEDICAL HOME ACCREDITATION
More informationChallenges in studying risk factors for childhood cancer
Challenges in studying risk factors for childhood cancer Julie A. Ross, Ph.D. Professor and Director, Division of Epidemiology & Clinical Research Department of Pediatrics, University of Minnesota & Masonic
More informationSKCC Protocol Review Committee New Study Application
Instructions: Submit the following documents to prc@jefferson.edu - Completed New Study Application (aka MCSF) - Protocol - Protocol Facilitation Committee Approval (if applicable) - MDG Priority Score
More informationIntroduction to Oncology and Chemotherapy October 23-24, 2013 San Francisco, CA
1 PROGRAM OUTLINE: Introduction to Oncology and Chemotherapy October 23-24, 2013 San Francisco, CA www.healthtech.com/ioc Description: Delegates attending this course will benefit from an introductory
More informationCancer Science nd International Conference on Oncology & Cancer Science. August 06-08, 2018 Berlin, Germany. Hosting Organization
Cancer Science 2018 2nd International Conference on Oncology & Cancer Science August 06-08, 2018 Berlin, Germany Hosting Organization Invitation Cenetri Publishing Group takes keen delectation and highly
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationFounded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options
Founded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options Integrated platform technology for discovery of novel molecular targets and
More informationCharacteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies
Characteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies Sabine Kayser, * Julia Krzykalla, Michelle A. Elliott, Kelly Norsworthy, Patrick Gonzales,
More informationThe conference will be held in English. There will be small group discussions and role play which requires proficiency in English
Course Announcement OSF Seminar on Palliative Care in Neurology with a special focus in Neuro-Oncology and the Neurological Complications of Cancer February 23 to March 1, 2014 The Open Society Foundation
More informationAmerican Cancer Society, Inc. Extramural Grants
Page: 1 Clinical Research Professorship (CRP) CRP-14-112-06 Chinnaiyan, Arul M., MD, PhD Department of Pathology and Urology Developing A Precision Medicine Framework for Cancer Patients 07/01/2014 $400,000
More informationPlease Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
More informationChildren s Oncology Group: What We Learned In The Merger Process
: What We Learned In The Merger Process Gregory H. Reaman, MD Professor of Pediatrics The George Washington University School of Medicine and Health Sciences PEDIATRIC ONCOLOGY GROUP Children s Oncology
More informationRESEARCH STUDY. Joan and Sanford I. Weill Medical College and Graduate School of Medical Sciences of Cornell University
RESEARCH STUDY Joan and Sanford I. Weill Medical College and Graduate School of Medical Sciences of Cornell University Genetic Study of Intellectual Disabilities and Autism Spectrum Disorders. The Weill
More informationSelinexor is an oral, slowly-reversible, first-inclass Selective Inhibitor of Nuclear Export (SINE)
Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes (MDS) Refractory to Hypomethylating Agents Justin Taylor, MD, Morgan Coleman, MPH, Kelsey
More informationCharacterization of TRK fusions and therapeutic response to TRK inhibition in hematologic malignancies
Characterization of TRK fusions and therapeutic response to TRK inhibition in hematologic malignancies Taylor J, 1 Yoshimi A 1, Marcelus C 1, Pavlick D 2, Benayed R 1, Cocco E 1, Durham BH 1, Hechtman
More informationI pediatric OncOlOgy
pediatric Oncology I Carlos Rodriguez-Galindo Matthew W. Wilson (Editors) Retinoblastoma With 52 Figures and 19 Tables IV Editors Carlos Rodriguez-Galindo, M.D Associate Professor of Pediatrics Dana-Farber
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationYoung Investigator Initiative for the Conduct of ACRIN Ancillary Research
Program Purpose ACRIN is pleased to announce an opportunity for junior faculty (assistant professors and instructors within the first seven years post-fellowship or post-training) to carry out an ancillary
More informationCancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
More informationThe Clinical Research E-News
Volume 3: ISSUE 4: March 2, 2011 The Clinical Research E-News Now Open: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study of
More informationBreast Cancer in Childhood Cancer Survivors: The Impact of Screening on Morbidity
Breast Cancer in Childhood Cancer Survivors: The Impact of Screening on Morbidity WORKING GROUP: This report will be written within the Cancer Control Working Group with oversight from the Second Malignant
More informationCompany Overview. April Rewriting cancer treatment NASDAQ: EPZM
Company Overview NASDAQ: EPZM Rewriting cancer treatment Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform
More informationOMI Seminars The Children's Hospital of Philadelpia TBA. Matt O'Connor, MD TBA. Weill Cornell Medicine-NYP TBA. Frank Chervenak, MD
1 January 7-13 Pediatric Cardiology * Matt O'Connor, MD The Children's Hospital of Philadelpia 629SPPS18 15.10.2017 2 January 14-20 OB/GYN Frank Chervenak, MD 630SWCS18 15.10.2017 3 January 21-27 Pediatric
More informationSeptember 20, Submitted electronically to: Cc: To Whom It May Concern:
History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).
More informationOnline/Self-study courses
Online/Self-study courses This list of CE offerings is not all inclusive. ONCC accepts many other accredited CE programs for ILNA Points. If you would like to know the applicability of a program not listed,
More informationDeveloping Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic. Kevin G. McLure, PhD EpiCongress July 2014
Developing Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic Kevin G. McLure, PhD EpiCongress July 2014 Zenith Epigenetics Overview Formed from Resverlogix as an independent
More informationOnline/Self study courses
Online/Self study courses This list of CE offerings is not all inclusive. ONCC accepts many other accredited CE programs for ILNA Points. If you would like to know the applicability of a program not listed,
More informationScarce Resources are best Applied to Prevention The Anti Argument
Scarce Resources are best Applied to Prevention The Anti Argument Lawrence N Shulman, MD Director, Center for Global Cancer Medicine Abramson Cancer Center, University of Pennsylvania Senior Oncology Advisor
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationJonathan H. Schatz, MD N Campbell Avenue, Tucson, AZ, (office), (laboratory)
Jonathan H. Schatz, MD Professional address and telephone: University of Arizona Cancer Center 1515 N Campbell Avenue, Tucson, AZ, 85724 schatzj@email.arizona.edu 520-626-2272 (office), 520-626-2217 (laboratory)
More informationBridging Treatment to Transplant and Current Advances
Memorial Sloan Kettering Cancer Center in partnership with The Bone Marrow Foundation and the National Marrow Donor Program (NMDP)/Be The Match present: Bridging Treatment to Transplant and Current Advances
More informationA World Free From Cancer. BC Cancer Foundation 2011 Report to Donors
A World Free From Cancer BC Cancer Foundation 2011 Report to Donors For the year ended March 31, 2011 Table of Contents Page 3 Page 5 Partners in Discovery A Message from the BC Cancer Foundation Chairman
More informationHR 95% Confidence Interval. *no DFS events occurred in AJCC 7 stage I/II TNBC patients treated with NPS plus trastuzumab.
NEWS RELEASE SELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2018 San Antonio Breast Cancer
More informationIntroduction to Oncology: Focus on Solid Tumors October 22-23, 2014 San Francisco, CA
Introduction to Oncology: Focus on Solid Tumors October 22-23, 2014 San Francisco, CA www.healthtech.com/ioc Description: Delegates attending this course will benefit from an introductory overview of the
More informationGenomic Methods in Cancer Epigenetic Dysregulation
Genomic Methods in Cancer Epigenetic Dysregulation Clara, Lyon 2018 Jacek Majewski, Associate Professor Department of Human Genetics, McGill University Montreal, Canada A few words about my lab Genomics
More informationRUNX1 and FPD/AML Translational Research. The Leukemia and Lymphoma Society / Babich Family Foundation Partnership. September 2016
www.lls.org www.runx1.com RUNX1 and FPD/AML Translational Research The Leukemia and Lymphoma Society / Babich Family Foundation Partnership September 2016 Prepared by L. Greenberger, PhD Chief Scientific
More informationAmerican Cancer Society, Inc. Extramural Grants
Page: 1 Doctoral Degree Scholarship in Cancer Nursing (DSCN) DSCN-16-064-01 Mann, Tara K., BSN MENTOR: Bailey, Donald (Chip) E., PhD, RN, FAAN Investigating Cognitive, Affective/Sleep Symptoms in Interleukin-2
More information2017 ST3 Competition Ratios Medical Specialties
2017 ST3 Competition Ratios Medical Specialties Applications Received Posts Available Competition Ratio Acute Internal Medicine 245 125 1.96 Allergy 8 3 2.67 Audiovestibular Medicine 9 1 9 Cardiology 361
More informationThe Advent of Immunotherapy in Cancer Therapy
The Memorial Hospital Alumni Society Presents The Advent of Immunotherapy in Cancer Therapy October 17-18, 2013 Rockefeller Research Laboratories 430 East 67th Street, New York, NY 10065 WT1 The Advent
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationComparative Effectiveness Research of Robotic Surgeries for Cancer Treatment
Comparative Effectiveness Research of Robotic Surgeries for Cancer Treatment Jim C. Hu MD, MPH Ronald Lynch Professor in Urologic Oncology Director of the LeFrak Center for Robotic Surgery 1 Objectives
More informationPast Chapter Summaries Educational Topics Summary
Below is a comprehensive summary of all of the different Educational Topics our Local Chapters have presented and/or provided 2014 1. The most powerful force in nursing 2. Hope and meaning in life in adolescent
More informationFrontiers in Cancer Therapy. John Glod, M.D., Ph.D.
Frontiers in Cancer Therapy John Glod, M.D., Ph.D. September 15, 2017 Objectives The Past: Alkylating agents The Present: Tyrosine Kinase Inhibitors The Future: Gene Expression, Metabolic cancers, CAR
More informationCSF1R Antibody LY , IMC-CS4. Drug Discovery Platform: Immuno-Oncology. Derived from Pixley FJ and Stanley ER. 1
CSF1R Antibody LY3022855, IMC-CS4 Derived from Pixley FJ and Stanley ER. 1 Drug Discovery Platform: Immuno-Oncology A Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients
More informationHODGKIN S AND NON-HODGKIN S LYMPHOMA
HODGKIN S AND NON-HODGKIN S LYMPHOMA edited by JOHN P. LEONARD, MD Center for Lymphoma and Myeloma Weill Medical College of Cornell University New York Presbyterian Hospital New York, NY MORTON COLEMAN,
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationNational Cancer Institute Clinical Trial Cooperative Groups
National Cancer Institute Clinical Trial Cooperative Groups Perspectives from the National Surgical Adjuvant Breast and Bowel Project Joyce Mull, MPM Director, Regulatory Affairs NSABP Foundation, Inc.
More informationPI3K/mTOR Dual Inhibitor
PI3K/mTOR Dual Inhibitor LY3023414 Courtney KD, et al 1 Drug Discovery Platform: Cancer Cell Signaling A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the
More informationCancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 19-21, 2016
Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC 20037 October 19-21, 2016 Wednesday, October 19, 2016 7:30 8:30 AM Registration
More informationOVAC FY 2017 Appropriations Requests
OVAC FY 2017 Appropriations Requests One Voice Against Cancer (OVAC), a broad coalition of cancer-related organizations representing millions of Americans, supports the goals of the Cancer Moonshot initiative
More informationSt. Rita s Cancer Service Line Annual Report
St. Rita s Cancer Service Line Annual Report St. Rita s comprehensive community cancer program provides integrated multi-disciplinary care. We are of team of professionals that uses leading-edge technology
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationInsights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Models
Insights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Models 4 th Annual International Erdheim-Chester Disease Medical Symposium Paris, France September 15, 2016 Benjamin
More informationThe Days of Miracles & Wonder... and Science
Memorial Sloan Kettering Cancer Center is pleased to announce a one day symposium honoring DR. RICHARD J. O REILLY The Days of Miracles & Wonder... and Science Friday, April 28, 2017 Zuckerman Research
More information2008 Oncology Pharmacy Preparatory Review Course Learning Objectives
2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationThursday, August 9, :00 am 5:30 pm Registration Desk Open Atlantic Ballroom Foyer. 7:00 am 8:00 am Continental Breakfast Atlantic Ballroom Foyer
Thursday, August 9, 2018 7:00 am 5:30 pm Registration Desk Open 7:00 am 8:00 am Continental Breakfast 8:00 am 8:10 am Welcome and Announcements 8:10 am 9:00 am Best of ASCO 1: Genitourinary Cancer Speaker:
More informationSU2C TOP SCIENCE ACCOMPLISHMENTS
SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over
More informationoncogenes-and- tumour-suppressor-genes)
Special topics in tumor biochemistry oncogenes-and- tumour-suppressor-genes) Speaker: Prof. Jiunn-Jye Chuu E-Mail: jjchuu@mail.stust.edu.tw Genetic Basis of Cancer Cancer-causing mutations Disease of aging
More information2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives
2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives Acute Leukemia/Tumor Lysis Syndrome John M. Valgus, Pharm.D., BCOP Hematology/Oncology Specialist University of North
More informationInnate Immunity Dysregulation in Myelodysplastic Syndromes. CONTRACTING ORGANIZATION: University of Texas MD Anderson Cancer Center Houston, TX 77030
AWARD NUMBER: W81XWH-12-1-0221 TITLE: Innate Immunity Dysregulation in Myelodysplastic Syndromes PRINCIPAL INVESTIGATOR: Yue Wei CONTRACTING ORGANIZATION: University of Texas MD Anderson Cancer Center
More informationExamining Genetics and Genomics of Acute Myeloid Leukemia in 2017
Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction
More informationOpposing effects of low versus high concentrations of vitamins/dietary ingredients Vitamin C and niacin on colon cancer stem cells (CSCs)
Opposing effects of low versus high concentrations of vitamins/dietary ingredients Vitamin C and niacin on colon cancer stem cells (CSCs) Colorectal cancer is one of the global causes of cancer deaths.
More informationTogether... The Strength to Fight Cancer. Annual Cancer Report December 2014
Together... The Strength to Fight Cancer Annual Cancer Report December 2014 2 Memorial Hospital and Health Care Center HOW DO YOU KNOW MEMORIAL HOSPITAL HAS HIGH QUALITY CANCER CARE? The American College
More informationChapter 3. Neoplasms. Copyright 2015 Cengage Learning.
Chapter 3 Neoplasms Terminology Related to Neoplasms and Tumors Neoplasm New growth Tumor Swelling or neoplasm Leukemia Malignant disease of bone marrow Hematoma Bruise or contusion Classification of Neoplasms
More informationResearch For the Future. Len Lichtenfeld, MD, MACP Interim Chief Medical and Scientific Officer
Research For the Future Len Lichtenfeld, MD, MACP Interim Chief Medical and Scientific Officer 1 2 ATTACKING CANCER FROM EVERY ANGLE 3 CANCER PREVENTION STUDIES (CPS) Intramural Research Smoking Obesity
More informationRECENT TRENDS. The Impact of the NCI and NIBIB
The Impact of the NCI and NIBIB James Deye, Ph.D. Program Director on Medical Physics RECENT TRENDS doubling of the NIH budget over last 5 years; appointment of new heads of NIH and NCI; creation of NIBIB;
More informationCancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development MicroTek Training Center Washington, DC October 17 19, 2018
Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development MicroTek Training Center Washington, DC October 17 19, 2018 Wednesday, October 17, 2018 8:00 8:30 AM Registration and Continental
More informationMedicinae Doctoris ~ One university. Many futures.
Medicinae Doctoris ~ 2018 Oncology Course M2 February 3, 2014 Dr. Gary Harding MD, FRCPC Medical Oncologist, Bioethicist Associate Dean, Accreditation Working Group Gary Harding: Oncology Vallerie Gordon:
More informationIdentifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas
Identifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas Mary T. Austin, MD, MPH Assistant Professor, Pediatric Surgery University of Texas Health Science
More informationMolecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationSAMPLE. Survivorship Care Plan for Lymphoma (Diffuse Large B-Cell) General Information. Care team
SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,
More informationEASTERN PAIN ASSOCIATION 2018 ANNUAL MEETING
EASTERN PAIN ASSOCIATION 2018 ANNUAL MEETING 7:15 7:55 AM Registration/Breakfast with Exhibitors and Posters 7:55 8:00 AM Welcome: President, Eastern Pain Association Naum Shaparin MD Director, Multidisciplinary
More informationTUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital)
Legend: Keynote Educational Meet the Expert (MTE) Paediatric Psycho-Oncology () Opening/Closing Award Session Free Paper Session (FPS) Session Satellite SIOPe GA SIOP ABM Late Breaker Session Networking
More informationRadiation Oncology Study Guide
Radiation Oncology Study Guide For the Initial CertificationQualifying (Computer-Based) Examination General and Radiation Oncology This examination is designed to assess your understanding of the entire
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationALBERTA PRINCIPAL INVESTIGATORS
ALBERTA PRINCIPAL INVESTIGATORS Dr. Gregory Cairncross is Head of the Department of Clinical Neurosciences at the University of Calgary and holder of the Alberta Cancer Foundation Chair in Brain Tumor
More informationCLINICAL RESEARCH IN GEORGIA UPDATE. Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014
CLINICAL RESEARCH IN GEORGIA UPDATE Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014 Georgia CORE is a public-private partnership dedicated to generating collaborative resources for
More informationChanges from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status
More information